Systemic Lupus Erythematosus :: Safety concern regarding Rituxan in systemic lupus erythematosus
The Food and Drug Administration (FDA) is alerting health care professionals and patients treated with Rituxan (rituximab) to reports of an emerging risk of a serious side effect in patients receiving or who have used Rituxan.
FDA recently learned that two patients who were treated [...]
Systemic Lupus Erythematosus :: Involvement of the amygdala in systemic lupus erythematosus
In a mouse model of systemic lupus erythematosus (SLE), anti-NMDA receptor antibodies have been shown to gain access to the brain during stress, specifically damaging the amygdala (a part of the brain that is involved in emotion) and causing altered emotional responses.
In a paper [...]
Sperm :: Sperm abnormalities seen in male lupus patients
The prognosis for systemic lupus erythematosus (SLE), an autoimmune disease that mainly affects women in their reproductive years, has improved recently, prompting a shift toward improving quality of life. For men with SLE, concerns have been raised about their future fertility.
However, no studies have been conducted to [...]
Systemic Lupus Erythematosus :: Interferon-regulated chemokines and SLE
A comprehensive survey of the serologic proteome in human SLE suggests that severely disrupted chemokine gradients may contribute to the systemic autoimmunity observed.
Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that is potentially debilitating and sometimes fatal as the immune system attacks the body?s cells [...]
Lymphoma :: Autoimmune diseases linked with Non-Hodgkin’s Lymphoma
According to a study published in the Journal of the National Cancer Institute, the risk of diffuse large B-cell lymphoma (a subtype of non-Hodgkin’s lymphoma) is elevated among patients with rheumatoid arthritis, Sj?gren syndrome, systemic lupus erythematosus, or celiac disease. Some of these conditions were also linked with [...]
Lupus :: Treatment with Belimumab showed improvement in symptoms in 46 percent of lupus patients at 52 weeks
Treatment with belimumab resulted in a sustained improvement of systemic lupus erythematosus disease activity in 46 percent of patients at week 52, according to a novel combined responder index in results presented today at EULAR 2007, the Annual [...]
Lupus :: Safety of Oral Contraceptives in Women with Lupus
In a major study funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), women with either inactive or stable systemic lupus erythematosus (lupus) – a disease in which the body’s immune system mistakenly [...]
Lupus :: Over one-third of refractory lupus patients remain stable at long term follow-up
Thirty-six percent of patients with refractory systemic lupus erythematosus remain well after undergoing B-cell depletion therapy without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Overactive B-cells are [...]
Lupus :: Older, lower income patients least likely to see a specialist for lupus
Despite advances in treatment, systemic lupus erythematosus (SLE) remains a serious disease. Previous studies have shown that racial and ethnic minorities and individuals with low socioeconomic status may have poorer outcomes in the long run.
Other research has shown that care provided by [...]
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| By N2H | |||||||||||||